Nevertheless, lenvatinib [28], regorafenib [29], ramucirumab [30] and cabozantinib [31], which recapitulate the mechanisms of sorafenib as VEGFR inhibitors, are expected to be approved for second-line treatment of advanced HCC in the United States and EU5, but not in the Asia-Pacific region. The gene discussed is KDR; the disease is hepatocellular carcinoma.